CA2440122C - Ultrasound method for revascularization and drug delivery - Google Patents
Ultrasound method for revascularization and drug delivery Download PDFInfo
- Publication number
- CA2440122C CA2440122C CA2440122A CA2440122A CA2440122C CA 2440122 C CA2440122 C CA 2440122C CA 2440122 A CA2440122 A CA 2440122A CA 2440122 A CA2440122 A CA 2440122A CA 2440122 C CA2440122 C CA 2440122C
- Authority
- CA
- Canada
- Prior art keywords
- interest
- area
- ultrasound device
- elongated flexible
- guidable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00392—Transmyocardial revascularisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
- A61M2025/0089—Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/058—General characteristics of the apparatus combined with other kinds of therapy with ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
- A61M2210/125—Heart
Abstract
A method and device for improving blood circulation to an area of interest within a patient's heart is described. The method comprises inserting a guidable elongated flexible ultrasound device into a patient's vasculature, applying ultrasonic energy to an area in need of improved circulation, and injecting materials such as angiogenic materials or contrasting agents into the area of interest. The device, suitable for performing the method, comprises an elongated tubular body, a distal head of the elongated tubular body for introducing ultrasonic energy to an area of interest, and a needle to deliver materials to an area of interest.
Description
ULTRASOUND METHOD FOR REVASCULARIZATION
AND DRUG DELIVERY
Background of the Invention 1. Technical Field of the Invention The present invention relates generally to medical devices for generating an angiogenic response in an interior wall of the heart using a percutaneous myocardial revascularization (PMR) procedure. More specifically, the ,present invention relates to an intravascular ultrasound PMR device having a needle for supplying the heart l0 with an angiogenic material or contrasting agent.
AND DRUG DELIVERY
Background of the Invention 1. Technical Field of the Invention The present invention relates generally to medical devices for generating an angiogenic response in an interior wall of the heart using a percutaneous myocardial revascularization (PMR) procedure. More specifically, the ,present invention relates to an intravascular ultrasound PMR device having a needle for supplying the heart l0 with an angiogenic material or contrasting agent.
2. Description of the Prior Art There is a great deal of interest in improving the methods for treating cardiovascular disease. Traditionally, cardiovascular disease has been treated using procedures such as cardiovascular bypass surgery, coronary angioplasty, laser angioplasty and atherectomy. These techniques generally are aimed at bypassing or opening lesions in coronary vessels so as to restore and increase blood flow to the heart. In some patients, the number of lesions is so great, or the location so remote in the patient's vasculature that restoring blood flow to the heart muscle is difficult.
2o Therefore, it is often the case that cardiovascular disease requires alternative treatment such as percutaneous myocardial revascularization (PMR).
PMR was developed as a less invasive alternative to bypass surgery. PMR
was inspired in part by observations that reptilian hearts are supplied primarily by blood perfusing directly from within heart chambers. In contrast, coronary vessels receiving blood from the aorta supply the human heart. PMR is performed by boring channels directly into the myocardium. This can be accomplished by a number of means including the insertion of a flexible catheter through the vasculature into the heart and boring holes into the myocardium. Positive results have been demonstrated in some human patients receiving these types of PMR treatments. These results are 3o believed to be caused in part by increased blood flowing from within a heart chamber through chamiels formed by PMR to the myocardial tissue. Increased blood flow to the myocardium is also believed to be caused in part by the healing response to wound formation. Specifically, the formation of new blood vessels is believed to occur in response to the newly created wound.
Suitable PMR holes have been burned by laser, cut by mechanical means, removed by ultrasound devices, and burned by radio frequency current devices in a technique called radio frequency percutaneous myocardial revascularization (RF-PMR).
In addition, catheter based needle injections of an angiogenic material directly into the myocardium has been developed in conjunction with RF-PMR. U.S. Patent No.
6,063,082 to DeVore et al. entitled "Percutaneous Myocardial Revascularization 1o Basket Delivery System and Radiofrequency Therapeutic Device" discloses a method in which an angiogenic material can be delivered into a hole recently burned by RF
current delivered through the needle. Unfortunately, in this method the angiogenic material may seep out of the hole created by the RF-PRM electrode, thus reducing the effectiveness of the angiogenic material.
U.S. Patent No. 5,827,203 to Nita entitled "Ultrasound system and Method For Myocardial Revascularization" discloses a method that uses ultrasonic energy to accomplish PMR. Ultrasound PMR offers advantages over other PMR techniques in that the method is less invasive and that in some embodiments no tissue needs to be removed. The application of ultrasonic energy to an area of interest produces a 2o thrombus required for angiogenesis without rupturing endocardial tissue.
However, this method currently lacks the ability to deliver additional interventions, such as the delivery of angiogenic materials, to an area of interest. Thus, physicians are limited in their ability to use this method and are required to form channels in the heart wall if massaging an area of interest does not produce the desired effect. Further, if massaging an area of interest is insufficient to induce myocardial revascularization, the ultrasound device is used to bore channels. By including a means for delivering angiogenic materials, the need for using the ultrasound device to bore channels should be reduced.
New research conducted by the applicant suggests that the thrombus, caused 3o by the application of ultrasonic energy, in and around the injury site contains the natural growth factors which cause the angiogenic response. Therefore, destruction of heart tissue, as with RF-PMR, may not be necessary to invoke an angiogenic response. Consequently, there is a need for a method of PMR that creates a natural angiogenic response without creating unnecessary injury to an area of interest.
Additionally, it would be beneficial for this method to be able to deliver additional angiogenic material to an area of interest in order to minimize both the destruction of cardiac tissue and seepage.
Summary of the Invention A preferred embodiment of the present invention provides a minimally invasive device for the treatment of cardiovascular disease via ultrasound myocardial 1o revascularization that additionally provides means for direct delivery of angiogenic materials. Combining ultrasound myocardial revascularization with an additional lumen for the delivery of angiogenic materials offers advantages over the prior art.
Since it is believed that the thrombus contains the natural growth factors capable of facilitating an angiogenic response, this invention can accentuate the body's own natural healing ability without destroying tissue. Further, since no myocardial tissue is destroyed, seepage of angiogenic materials is minimized. Finally, a contrasting agent can be delivered through the needle to enable the physician to image an area of interest.
In one embodiment of this invention, a needle is attached to the ultrasound 2o PMR device adjacent to the catheter along the catheter's longitudinal axis.
Angiagenic materials or a contrasting agent can be delivered to an area of interest through the needle.
In another embodiment, the needle passes through the lumen of the ultrasound catheter. Angiogenic materials or a contrasting agent can be delivered to an area of interest through the needle.
Brief Description of the Drawings Figure 1 is a perspective view of an ultrasound PMR catheter system wherein a needle is attached adjacent to the ultrasound catheter along the catheter's 3o longitudinal axis;
Figure 2 is a schematic section of a human heart showing percutaneous revascularization of the myocardium according to the present invention; and Figure 3 is a perspective view of an ultrasound PMR catheter system wherein a needle is attached within the lumen of the ultrasound catheter.
Detailed Description of the Preferred Embodiments Refernng now to the drawings wherein like reference numerals refer to like elements throughout the several views, Figure 1 illustrates a guidable elongated flexible ultrasound device for increasing blood circulation to an area of interest within the heart of a patient. The guidable elongated flexible ultrasound device includes an elongated tubular body 10 with a proximal end closest to the outside of the body and a to distal end closest to an area of interest within a patient's heart. In the preferred embodiment, the elongated tubular body 10 is constructed of flexible material to easily pass through turns of the vasculature. The elongated tubular body 10 has at least one lumen 12, extending along the longitudinal axis 14 thereof.
The distal head 16 of the elongated tubular body includes an ultrasonic catheter device that can be connected to a signal generator by an ultrasound transmission lead 18. As such, when a signal generator sends ultrasonic energy through the ultrasound transmission lead 18, ultrasonic energy will pass through the distal head 16 to an area of interest and can be used to massage the myocardium 30.
More specifically, the ultrasound transmission lead 18 serves to transmit ultrasonic 2o energy from the proximal end of the elongated flexible ultrasound device to the distal head 16 of the elongated tubular body 10, and then to an area of interest.
The guidable elongated flexible ultrasound device can reach an area of interest by first inserting a guidewire 19 into the patient's vasculature and passing the elongated tubular body 10 over said guidewire 19. In the preferred embodiment, the guidewire 19 can pass through a lumen within the elongated tubular body ranging from the elongated tubular body's far proximal end through the distal head and then through a lumen 21 within said distal head. One skilled in the art can insert the guidewire 19 through a patient's vasculature and into the patient's heart to an area of interest. Then, the elongated tubular body 10 can be passed over said guidewire 19 3o through a lumen therein to an area of interest.
Mounted adjacent to the elongated tubular body 10 is a needle 20 with a lumen 22 fox injecting material 24 near a thrombus 26. In the preferred embodiment, the needle is constructed of stainless steel. The lumen 22 of the needle 20 is of sufficient diameter to allow passage of angiogenic materials or contrasting agents.
Angiogenic materials comprise a plethora of substances including but not limited to pharmaceutically active compounds, nucleic acids (including polynucleotide sequences), peptides (including polypeptides and proteins), oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, and gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids).
For example, nucleic acids that may comprise angiogenic materials include anti-sense DNA and RNA, DNA coding for an anti-sense RNA, or DNA coding for 1o tRNA, or rRNA to replace defective or deficient endogenous molecules. The angiogenic polynucleotides may also code for therapeutic peptides, polypeptides and proteins. A polypeptide is understood to be any translational product of a polynucleotide regardless of size, and whether glycosylated or not.
Therapeutic polypeptides that may act as angiogenic factors including acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor a, and (3, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor a, hepatocyte growth factor and insulin like growth factor; growth factors; cell cycle inhibitors including CDK inhibitors; thymidine kinase ("TK") and other agents useful for interfering with cell proliferation, including agents for treating malignancies; and combinations thereof.
In another embodiment of the present invention, angiogenic materials may include a viral vector having linked thereto an exogenous nucleic acid sequence.
"Exogenous nucleic acid sequence" is used herein to mean a sequence of nucleic acids that is exogenous to the virus from which the vector is derived. The concentration of the vixal vector, preferably an adenoviral vector, is at least about 101° plaque forming units ("p.f.u."), or limited by the concentration that results in an undesirable immune response from a patient.
Contrasting agents comprise substances including but not limited to those that 3o enable a physician performing the method or using the device to accumulate information useful for completing or evaluating the procedure. Example of contrasting agents include but are not limited to saline (0.9% NaCl) that can flood the tip of the guidable elongated flexible ultrasound device so as to enable visualization of an area of interest or the device's location within the vasculature, radioactive or radiolabeled magnetic compounds useful for tracing during or after performing the method, and anti-thrombin or blood thinning compounds (including heparin, heparin derivatives, urokinase, dextrophenylalanine proline arginine chloromethylketone, rapamycin, probucol, and verapamil).
Applying ultrasonic energy to the endocardial layer 28 of the myocardium 30 generates the thrombus 26. One skilled in the art can massage the myocardium with ultrasonic energy emitted through the distal head 16 of the elongated tubular to body 10. When ultrasonic energy is applied to the myocardium 30, it causes relaxation of the cardiac muscle and vasodilation (relaxation of the vasculature that may result in increased blood flow to the area wherein ultrasonic energy is used upon). In an embodiment of the invention, when the myocardium 30 is massaged, preferably no heart tissue or an insignificant amount is removed from the endocardium 28. A sufficient amount of massaging can lead to the formation of at least one thrombus 26 wherein blot clotting and wound healing can take place and lead to myocardial revascularization. Once a thrombus is formed, the needle 20 can be used to deliver angiogenic materials or contrasting agents that may accentuate the body's natural ability to promote revascularization and/or wound healing.
The guidable elongated flexible ultrasound device also includes an endoscopic visualization device 32 for visualizing an area of interest. The device extends longitudinally through the lumen 22 of the elongated tubular body 10 and comprises an outer sheath having at least one image transmitting optical fiber bundle and possibly one or more additional fiber bundles extending longitudinally throughout.
The image transmitting optical fiber bundle in encircled by a plurality of light transmitting optical fiber bundles that also extend longitudinally along the outer sheath. At its proximal end, the visualization device is connected to at least one machine that may be suitable for allowing a physician skilled in the art to visualize an area of interest or the present location within the vasculature of the guidable elongated 3o flexible ultrasound device.
Figure 2 illustrates a schematic of a human heart 40 showing percutaneous revascularization of the myocardium 30 using the invention drawn in Figure 1.
The distal head 16 of the elongated tubular body 10 is inserted percutaneously into a major blood vessel (such as the femoral arterial or another peripheral vessel), into and through the aorta 44 to the heart 40, and into a ventricle 46 to an area in need of increased blood circulation 48. Ultrasonic energy from the distal head 16 is used to massage an area of interest so as to generate a thrombus. Angiogenic materials or contrasting agents can then be injected through the needle 20 mounted adjacent to the elongated tubular body 10 through the endocardium 28 and into or near the thrombus.
Figure 3 illustrates an embodiment of a guidable elongated flexible ultrasound device similar to that drawn in Figure 1. The guidable elongated flexible ultrasound device includes an elongated tubular body 110 with at least one lumen 112, with a proximal end closest to the outside of the body and a distal end closest to an area of interest within a patient's heart. The distal head 116 of the elongated tubular body includes an ultrasonic catheter device that can be connected to a signal generator by an ultrasound transmission lead 18. Ultrasonic energy can pass through the distal head 116 via the ultrasound transmission lead to an area of interest and can be used to massage the myocardium 30. A sufficient amount of massaging can lead to the formation of at least one thrombus 26 wherein blot clotting and wound healing can take place and lead to myocardial revascularization.
The guidable elongated flexible ultrasound device also includes an 2o endoscopic visualization device 32 for visualizing said area of interest.
The device extends longitudinally through the lumen 122 of the elongated tubular body 110 and comprises an outer sheath having at least one image transmitting optical fiber bundle and possibly one or more additional fiber bundles extending longitudinally throughout. At its proximal end, the visualization device can be connected to at least one machine suitable for allowing a physician skilled in the art to visualize an area of interest or the present location within the vasculature of the guidable elongated flexible ultrasound device.
The guidable elongated flexible ultrasound device can reach an area of interest by first inserting a guidewire 19 into the patient's vasculature and passing the 3o elongated tubular body 110 over said guidewire 19. In the preferred embodiment, the guidewire 19 can pass through a lumen within the elongated tubular body ranging from the elongated tubular body's far proximal end through the distal head and then through a lumen 121 within said distal head. Then, the elongated tubular body can be passed over said guidewire 19 through a lumen therein to an area of interest.
In the current embodiment, a needle 120 for injecting materials 124 into or near a thrombus 26 is mounted within the lumen 112 of the elongated tubular body 110 and passes through the distal head 116. The distal head 116 still retains its ability to transmit ultrasonic energy so as to generate at least one thrombus 26 within the myocardium 30. The lumen 122 of the needle 120 is of sufficient diameter to allow passage of angiogenic materials or contrasting agent. Angiogenic materials may include pharmaceutically active compounds, nucleic acids (including polynucleotide l0 sequences), peptides (including polypeptides and proteins), oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, and gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids) including but not limited to those listed previously. Contrasting agents may include saline, radioactive compounds, and anti-thrombin compounds including but not limited to those listed previously.
Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
2o Therefore, it is often the case that cardiovascular disease requires alternative treatment such as percutaneous myocardial revascularization (PMR).
PMR was developed as a less invasive alternative to bypass surgery. PMR
was inspired in part by observations that reptilian hearts are supplied primarily by blood perfusing directly from within heart chambers. In contrast, coronary vessels receiving blood from the aorta supply the human heart. PMR is performed by boring channels directly into the myocardium. This can be accomplished by a number of means including the insertion of a flexible catheter through the vasculature into the heart and boring holes into the myocardium. Positive results have been demonstrated in some human patients receiving these types of PMR treatments. These results are 3o believed to be caused in part by increased blood flowing from within a heart chamber through chamiels formed by PMR to the myocardial tissue. Increased blood flow to the myocardium is also believed to be caused in part by the healing response to wound formation. Specifically, the formation of new blood vessels is believed to occur in response to the newly created wound.
Suitable PMR holes have been burned by laser, cut by mechanical means, removed by ultrasound devices, and burned by radio frequency current devices in a technique called radio frequency percutaneous myocardial revascularization (RF-PMR).
In addition, catheter based needle injections of an angiogenic material directly into the myocardium has been developed in conjunction with RF-PMR. U.S. Patent No.
6,063,082 to DeVore et al. entitled "Percutaneous Myocardial Revascularization 1o Basket Delivery System and Radiofrequency Therapeutic Device" discloses a method in which an angiogenic material can be delivered into a hole recently burned by RF
current delivered through the needle. Unfortunately, in this method the angiogenic material may seep out of the hole created by the RF-PRM electrode, thus reducing the effectiveness of the angiogenic material.
U.S. Patent No. 5,827,203 to Nita entitled "Ultrasound system and Method For Myocardial Revascularization" discloses a method that uses ultrasonic energy to accomplish PMR. Ultrasound PMR offers advantages over other PMR techniques in that the method is less invasive and that in some embodiments no tissue needs to be removed. The application of ultrasonic energy to an area of interest produces a 2o thrombus required for angiogenesis without rupturing endocardial tissue.
However, this method currently lacks the ability to deliver additional interventions, such as the delivery of angiogenic materials, to an area of interest. Thus, physicians are limited in their ability to use this method and are required to form channels in the heart wall if massaging an area of interest does not produce the desired effect. Further, if massaging an area of interest is insufficient to induce myocardial revascularization, the ultrasound device is used to bore channels. By including a means for delivering angiogenic materials, the need for using the ultrasound device to bore channels should be reduced.
New research conducted by the applicant suggests that the thrombus, caused 3o by the application of ultrasonic energy, in and around the injury site contains the natural growth factors which cause the angiogenic response. Therefore, destruction of heart tissue, as with RF-PMR, may not be necessary to invoke an angiogenic response. Consequently, there is a need for a method of PMR that creates a natural angiogenic response without creating unnecessary injury to an area of interest.
Additionally, it would be beneficial for this method to be able to deliver additional angiogenic material to an area of interest in order to minimize both the destruction of cardiac tissue and seepage.
Summary of the Invention A preferred embodiment of the present invention provides a minimally invasive device for the treatment of cardiovascular disease via ultrasound myocardial 1o revascularization that additionally provides means for direct delivery of angiogenic materials. Combining ultrasound myocardial revascularization with an additional lumen for the delivery of angiogenic materials offers advantages over the prior art.
Since it is believed that the thrombus contains the natural growth factors capable of facilitating an angiogenic response, this invention can accentuate the body's own natural healing ability without destroying tissue. Further, since no myocardial tissue is destroyed, seepage of angiogenic materials is minimized. Finally, a contrasting agent can be delivered through the needle to enable the physician to image an area of interest.
In one embodiment of this invention, a needle is attached to the ultrasound 2o PMR device adjacent to the catheter along the catheter's longitudinal axis.
Angiagenic materials or a contrasting agent can be delivered to an area of interest through the needle.
In another embodiment, the needle passes through the lumen of the ultrasound catheter. Angiogenic materials or a contrasting agent can be delivered to an area of interest through the needle.
Brief Description of the Drawings Figure 1 is a perspective view of an ultrasound PMR catheter system wherein a needle is attached adjacent to the ultrasound catheter along the catheter's 3o longitudinal axis;
Figure 2 is a schematic section of a human heart showing percutaneous revascularization of the myocardium according to the present invention; and Figure 3 is a perspective view of an ultrasound PMR catheter system wherein a needle is attached within the lumen of the ultrasound catheter.
Detailed Description of the Preferred Embodiments Refernng now to the drawings wherein like reference numerals refer to like elements throughout the several views, Figure 1 illustrates a guidable elongated flexible ultrasound device for increasing blood circulation to an area of interest within the heart of a patient. The guidable elongated flexible ultrasound device includes an elongated tubular body 10 with a proximal end closest to the outside of the body and a to distal end closest to an area of interest within a patient's heart. In the preferred embodiment, the elongated tubular body 10 is constructed of flexible material to easily pass through turns of the vasculature. The elongated tubular body 10 has at least one lumen 12, extending along the longitudinal axis 14 thereof.
The distal head 16 of the elongated tubular body includes an ultrasonic catheter device that can be connected to a signal generator by an ultrasound transmission lead 18. As such, when a signal generator sends ultrasonic energy through the ultrasound transmission lead 18, ultrasonic energy will pass through the distal head 16 to an area of interest and can be used to massage the myocardium 30.
More specifically, the ultrasound transmission lead 18 serves to transmit ultrasonic 2o energy from the proximal end of the elongated flexible ultrasound device to the distal head 16 of the elongated tubular body 10, and then to an area of interest.
The guidable elongated flexible ultrasound device can reach an area of interest by first inserting a guidewire 19 into the patient's vasculature and passing the elongated tubular body 10 over said guidewire 19. In the preferred embodiment, the guidewire 19 can pass through a lumen within the elongated tubular body ranging from the elongated tubular body's far proximal end through the distal head and then through a lumen 21 within said distal head. One skilled in the art can insert the guidewire 19 through a patient's vasculature and into the patient's heart to an area of interest. Then, the elongated tubular body 10 can be passed over said guidewire 19 3o through a lumen therein to an area of interest.
Mounted adjacent to the elongated tubular body 10 is a needle 20 with a lumen 22 fox injecting material 24 near a thrombus 26. In the preferred embodiment, the needle is constructed of stainless steel. The lumen 22 of the needle 20 is of sufficient diameter to allow passage of angiogenic materials or contrasting agents.
Angiogenic materials comprise a plethora of substances including but not limited to pharmaceutically active compounds, nucleic acids (including polynucleotide sequences), peptides (including polypeptides and proteins), oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, and gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids).
For example, nucleic acids that may comprise angiogenic materials include anti-sense DNA and RNA, DNA coding for an anti-sense RNA, or DNA coding for 1o tRNA, or rRNA to replace defective or deficient endogenous molecules. The angiogenic polynucleotides may also code for therapeutic peptides, polypeptides and proteins. A polypeptide is understood to be any translational product of a polynucleotide regardless of size, and whether glycosylated or not.
Therapeutic polypeptides that may act as angiogenic factors including acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor a, and (3, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor a, hepatocyte growth factor and insulin like growth factor; growth factors; cell cycle inhibitors including CDK inhibitors; thymidine kinase ("TK") and other agents useful for interfering with cell proliferation, including agents for treating malignancies; and combinations thereof.
In another embodiment of the present invention, angiogenic materials may include a viral vector having linked thereto an exogenous nucleic acid sequence.
"Exogenous nucleic acid sequence" is used herein to mean a sequence of nucleic acids that is exogenous to the virus from which the vector is derived. The concentration of the vixal vector, preferably an adenoviral vector, is at least about 101° plaque forming units ("p.f.u."), or limited by the concentration that results in an undesirable immune response from a patient.
Contrasting agents comprise substances including but not limited to those that 3o enable a physician performing the method or using the device to accumulate information useful for completing or evaluating the procedure. Example of contrasting agents include but are not limited to saline (0.9% NaCl) that can flood the tip of the guidable elongated flexible ultrasound device so as to enable visualization of an area of interest or the device's location within the vasculature, radioactive or radiolabeled magnetic compounds useful for tracing during or after performing the method, and anti-thrombin or blood thinning compounds (including heparin, heparin derivatives, urokinase, dextrophenylalanine proline arginine chloromethylketone, rapamycin, probucol, and verapamil).
Applying ultrasonic energy to the endocardial layer 28 of the myocardium 30 generates the thrombus 26. One skilled in the art can massage the myocardium with ultrasonic energy emitted through the distal head 16 of the elongated tubular to body 10. When ultrasonic energy is applied to the myocardium 30, it causes relaxation of the cardiac muscle and vasodilation (relaxation of the vasculature that may result in increased blood flow to the area wherein ultrasonic energy is used upon). In an embodiment of the invention, when the myocardium 30 is massaged, preferably no heart tissue or an insignificant amount is removed from the endocardium 28. A sufficient amount of massaging can lead to the formation of at least one thrombus 26 wherein blot clotting and wound healing can take place and lead to myocardial revascularization. Once a thrombus is formed, the needle 20 can be used to deliver angiogenic materials or contrasting agents that may accentuate the body's natural ability to promote revascularization and/or wound healing.
The guidable elongated flexible ultrasound device also includes an endoscopic visualization device 32 for visualizing an area of interest. The device extends longitudinally through the lumen 22 of the elongated tubular body 10 and comprises an outer sheath having at least one image transmitting optical fiber bundle and possibly one or more additional fiber bundles extending longitudinally throughout.
The image transmitting optical fiber bundle in encircled by a plurality of light transmitting optical fiber bundles that also extend longitudinally along the outer sheath. At its proximal end, the visualization device is connected to at least one machine that may be suitable for allowing a physician skilled in the art to visualize an area of interest or the present location within the vasculature of the guidable elongated 3o flexible ultrasound device.
Figure 2 illustrates a schematic of a human heart 40 showing percutaneous revascularization of the myocardium 30 using the invention drawn in Figure 1.
The distal head 16 of the elongated tubular body 10 is inserted percutaneously into a major blood vessel (such as the femoral arterial or another peripheral vessel), into and through the aorta 44 to the heart 40, and into a ventricle 46 to an area in need of increased blood circulation 48. Ultrasonic energy from the distal head 16 is used to massage an area of interest so as to generate a thrombus. Angiogenic materials or contrasting agents can then be injected through the needle 20 mounted adjacent to the elongated tubular body 10 through the endocardium 28 and into or near the thrombus.
Figure 3 illustrates an embodiment of a guidable elongated flexible ultrasound device similar to that drawn in Figure 1. The guidable elongated flexible ultrasound device includes an elongated tubular body 110 with at least one lumen 112, with a proximal end closest to the outside of the body and a distal end closest to an area of interest within a patient's heart. The distal head 116 of the elongated tubular body includes an ultrasonic catheter device that can be connected to a signal generator by an ultrasound transmission lead 18. Ultrasonic energy can pass through the distal head 116 via the ultrasound transmission lead to an area of interest and can be used to massage the myocardium 30. A sufficient amount of massaging can lead to the formation of at least one thrombus 26 wherein blot clotting and wound healing can take place and lead to myocardial revascularization.
The guidable elongated flexible ultrasound device also includes an 2o endoscopic visualization device 32 for visualizing said area of interest.
The device extends longitudinally through the lumen 122 of the elongated tubular body 110 and comprises an outer sheath having at least one image transmitting optical fiber bundle and possibly one or more additional fiber bundles extending longitudinally throughout. At its proximal end, the visualization device can be connected to at least one machine suitable for allowing a physician skilled in the art to visualize an area of interest or the present location within the vasculature of the guidable elongated flexible ultrasound device.
The guidable elongated flexible ultrasound device can reach an area of interest by first inserting a guidewire 19 into the patient's vasculature and passing the 3o elongated tubular body 110 over said guidewire 19. In the preferred embodiment, the guidewire 19 can pass through a lumen within the elongated tubular body ranging from the elongated tubular body's far proximal end through the distal head and then through a lumen 121 within said distal head. Then, the elongated tubular body can be passed over said guidewire 19 through a lumen therein to an area of interest.
In the current embodiment, a needle 120 for injecting materials 124 into or near a thrombus 26 is mounted within the lumen 112 of the elongated tubular body 110 and passes through the distal head 116. The distal head 116 still retains its ability to transmit ultrasonic energy so as to generate at least one thrombus 26 within the myocardium 30. The lumen 122 of the needle 120 is of sufficient diameter to allow passage of angiogenic materials or contrasting agent. Angiogenic materials may include pharmaceutically active compounds, nucleic acids (including polynucleotide l0 sequences), peptides (including polypeptides and proteins), oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, and gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids) including but not limited to those listed previously. Contrasting agents may include saline, radioactive compounds, and anti-thrombin compounds including but not limited to those listed previously.
Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
Claims (21)
1. Use of a guidable elongated flexible ultrasound device for improving blood circulation to an area of interest in a heart muscle of a patient, wherein:
said guidable elongated flexible ultrasound device comprises an elongate lumen, a distal end, a proximal end, a distal head mounted on said distal end, and a needle mounted to said elongated tubular body in fluid communication with said lumen;
wherein said distal head is adapted for engaging, but not piercing, the area of interest and for use to apply ultrasonic energy to said area of interest to create a thrombus without the removal of heart material from the area of interest; and said needle is adapted for use to inject a material into said area of interest.
said guidable elongated flexible ultrasound device comprises an elongate lumen, a distal end, a proximal end, a distal head mounted on said distal end, and a needle mounted to said elongated tubular body in fluid communication with said lumen;
wherein said distal head is adapted for engaging, but not piercing, the area of interest and for use to apply ultrasonic energy to said area of interest to create a thrombus without the removal of heart material from the area of interest; and said needle is adapted for use to inject a material into said area of interest.
2. The use according to claim 1, wherein said material is an angiogenic material.
3. The use according to claim 1, wherein said material is a contrasting agent.
4. The use according to any one of claims 1 to 3, wherein the ultrasonic energy is adapted for massaging said area of interest without removing any portion of said heart muscle at said area of interest.
5. The use according to any one of claims 1 to 4, wherein said needle is attached adjacent to said distal head.
6. The use according to any one of claims 1 to 4, wherein said needle extends from said distal head.
7. The use according to any one of claims 1 to 6, wherein said guidable elongated flexible ultrasound device further comprises a guidewire adapted for insertion into said patient's vasculature so that said guidable elongated flexible ultrasound device may be passed over said guidewire.
8. The use according to any one of claims 1 to 7, wherein said guidable elongated flexible ultrasound device includes an endoscopic visualization device for visualizing said area of interest.
9. Use of a guidable elongated flexible ultrasound device for improving blood circulation to an external area of interest in a heart muscle of a patient, wherein:
said guidable elongated flexible ultrasound device comprises an elongate lumen, a distal end, a proximal end, a distal head mounted on said distal end, and a needle with a lumen mounted to said elongated tubular body in fluid communication with said lumen;
wherein said distal head is adapted for use to contact said exterior area of interest of said heart muscle and to apply ultrasonic energy to said external area of interest; and said needle is adapted for use to inject a material into said area of interest.
said guidable elongated flexible ultrasound device comprises an elongate lumen, a distal end, a proximal end, a distal head mounted on said distal end, and a needle with a lumen mounted to said elongated tubular body in fluid communication with said lumen;
wherein said distal head is adapted for use to contact said exterior area of interest of said heart muscle and to apply ultrasonic energy to said external area of interest; and said needle is adapted for use to inject a material into said area of interest.
10. A guidable elongated flexible ultrasound device for increasing the blood circulation to an area of interest in a heart muscle of a patient comprising:
an elongated tubular body having a lumen, a longitudinal axis, a distal end and a proximal end;
a distal head mounted on said distal end for engaging, but not piercing, the area of interest and for introducing ultrasonic waves to said area of interest to create a thrombus without the removal of heart material from the area of interest; and a needle for injecting a material into said area of interest, said needle mounted to said elongated tubular body substantially parallel to said longitudinal axis of said tubular body.
an elongated tubular body having a lumen, a longitudinal axis, a distal end and a proximal end;
a distal head mounted on said distal end for engaging, but not piercing, the area of interest and for introducing ultrasonic waves to said area of interest to create a thrombus without the removal of heart material from the area of interest; and a needle for injecting a material into said area of interest, said needle mounted to said elongated tubular body substantially parallel to said longitudinal axis of said tubular body.
11. The guidable elongated flexible ultrasound device as recited in claim 10, wherein said material is an angiogenic material.
12. The guidable elongated flexible ultrasound device as recited in claim 11, wherein said material is a contrasting agent.
13. The guidable elongated flexible ultrasound device of claim 10, wherein said needle is attached adjacent to said elongated tubular body.
14. The guidable elongated flexible ultrasound device of claim 10, wherein said needle is attached to said elongated tubular body within said lumen of said elongated tubular body.
15. The guidable elongated flexible ultrasound device of claim 10, further comprising a guidewire for inserting into said patient's vasculature and passing said guidable elongated flexible ultrasound device over said guidewire.
16. A system for increasing the blood circulation to an area of interest in a heart muscle of a patient comprising:
an elongated tubular body having a lumen, a longitudinal axis, a distal end and a proximal end;
a distal head mounted on said distal end for introducing ultrasonic waves to said area of interest;
a signal generator and an ultrasonic transmission lead coupled to the distal head, the signal generator provision signals to the distal head that cause the distal head to apply ultrasonic signals to the area of interest to create a thrombus without the removal of heart material from the area of interest; and a needle for injecting a material into or adjacent said thrombus.
an elongated tubular body having a lumen, a longitudinal axis, a distal end and a proximal end;
a distal head mounted on said distal end for introducing ultrasonic waves to said area of interest;
a signal generator and an ultrasonic transmission lead coupled to the distal head, the signal generator provision signals to the distal head that cause the distal head to apply ultrasonic signals to the area of interest to create a thrombus without the removal of heart material from the area of interest; and a needle for injecting a material into or adjacent said thrombus.
17. The guidable elongated flexible ultrasound device as recited in claim 16, wherein said material is an angiogenic material.
18. The guidable elongated flexible ultrasound device as recited in claim 17, wherein said material is a contrasting agent.
19. The guidable elongated flexible ultrasound device of claim 16, wherein said needle is attached adjacent to said elongated tubular body.
20. The guidable elongated flexible ultrasound device of claim 16, wherein said needle is attached to said elongated tubular body within said lumen of said elongated tubular body.
21. The guidable elongated flexible ultrasound device of claim 16, further comprising a guidewire for inserting into said patient's vasculature and passing said guidable elongated flexible ultrasound device over said guidewire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/808,624 US6508783B2 (en) | 2001-03-14 | 2001-03-14 | Ultrasound method for revascularization and drug delivery |
| US09/808,624 | 2001-03-14 | ||
| PCT/US2002/003589 WO2002074175A2 (en) | 2001-03-14 | 2002-02-07 | Ultrasound system and method for revascularization and drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2440122A1 CA2440122A1 (en) | 2002-09-26 |
| CA2440122C true CA2440122C (en) | 2011-08-02 |
Family
ID=25199295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2440122A Expired - Fee Related CA2440122C (en) | 2001-03-14 | 2002-02-07 | Ultrasound method for revascularization and drug delivery |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6508783B2 (en) |
| EP (1) | EP1370182A2 (en) |
| JP (1) | JP4125130B2 (en) |
| AU (1) | AU2002242120A1 (en) |
| CA (1) | CA2440122C (en) |
| WO (1) | WO2002074175A2 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU721034B2 (en) * | 1996-02-15 | 2000-06-22 | Biosense, Inc. | Catheter based surgery |
| US6421708B2 (en) * | 1998-07-31 | 2002-07-16 | Glenayre Electronics, Inc. | World wide web access for voice mail and page |
| US6854467B2 (en) * | 2000-05-04 | 2005-02-15 | Percardia, Inc. | Methods and devices for delivering a ventricular stent |
| US20020032478A1 (en) * | 2000-08-07 | 2002-03-14 | Percardia, Inc. | Myocardial stents and related methods of providing direct blood flow from a heart chamber to a coronary vessel |
| US6508783B2 (en) * | 2001-03-14 | 2003-01-21 | Scimed Life Systems, Inc. | Ultrasound method for revascularization and drug delivery |
| US20030036698A1 (en) * | 2001-08-16 | 2003-02-20 | Robert Kohler | Interventional diagnostic catheter and a method for using a catheter to access artificial cardiac shunts |
| US6949118B2 (en) * | 2002-01-16 | 2005-09-27 | Percardia, Inc. | Encased implant and methods |
| US7008397B2 (en) * | 2002-02-13 | 2006-03-07 | Percardia, Inc. | Cardiac implant and methods |
| US20030220661A1 (en) * | 2002-05-21 | 2003-11-27 | Heartstent Corporation | Transmyocardial implant delivery system |
| US7326219B2 (en) * | 2002-09-09 | 2008-02-05 | Wilk Patent Development | Device for placing transmyocardial implant |
| US20060058708A1 (en) * | 2003-12-24 | 2006-03-16 | Gill Heart | Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue |
| EP1763321A4 (en) * | 2004-04-16 | 2010-02-17 | Critical Care Innovations Inc | Systems and methods for improving image-guided tissue ablation |
| US7151285B2 (en) * | 2004-06-30 | 2006-12-19 | Micron Technology, Inc. | Transistor structures and transistors with a germanium-containing channel |
| US8252016B2 (en) | 2005-01-13 | 2012-08-28 | Azam Anwar | System and method for providing embolic protection |
| US20060200168A1 (en) * | 2005-03-03 | 2006-09-07 | Azam Anwar | System and method for providing access in divergent directions in a vascular environment |
| US20070021653A1 (en) * | 2005-06-27 | 2007-01-25 | Lars-Olof Hattenbach | Device for the injection of drugs into microvessels |
| ATE375808T1 (en) * | 2005-06-27 | 2007-11-15 | Lars-Olof Hattenbach | DEVICE FOR INJECTING MEDICATIONS INTO MICRO VESSELS |
| US20080086159A1 (en) * | 2006-06-21 | 2008-04-10 | Zweifler Michael D | Apparatus and method for reducing or eliminating the pain associated with an injection |
| US8545440B2 (en) | 2007-12-21 | 2013-10-01 | Carticept Medical, Inc. | Injection system for delivering multiple fluids within the anatomy |
| US8002736B2 (en) * | 2007-12-21 | 2011-08-23 | Carticept Medical, Inc. | Injection systems for delivery of fluids to joints |
| US9044542B2 (en) | 2007-12-21 | 2015-06-02 | Carticept Medical, Inc. | Imaging-guided anesthesia injection systems and methods |
| US10765473B2 (en) | 2010-11-08 | 2020-09-08 | Baylis Medical Company Inc. | Electrosurgical device having a lumen |
| US11937873B2 (en) | 2013-03-12 | 2024-03-26 | Boston Scientific Medical Device Limited | Electrosurgical device having a lumen |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4790311A (en) | 1986-06-03 | 1988-12-13 | Ruiz Oscar F | Radio frequency angioplasty catheter system |
| US5588432A (en) | 1988-03-21 | 1996-12-31 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials, and ablating tissue |
| US5807388A (en) | 1994-05-25 | 1998-09-15 | The Trustees Of Columbia University In The City Of New York | Myocardial revascularization through the endocardial surface using a laser |
| NZ272209A (en) | 1991-05-01 | 2001-02-23 | Univ Columbia | Myocardial revascularisation of the heart by a laser |
| US5697882A (en) | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
| US5683366A (en) | 1992-01-07 | 1997-11-04 | Arthrocare Corporation | System and method for electrosurgical tissue canalization |
| US5318014A (en) * | 1992-09-14 | 1994-06-07 | Coraje, Inc. | Ultrasonic ablation/dissolution transducer |
| CA2165829A1 (en) | 1993-07-01 | 1995-01-19 | John E. Abele | Imaging, electrical potential sensing, and ablation catheters |
| US5681308A (en) | 1994-06-24 | 1997-10-28 | Stuart D. Edwards | Ablation apparatus for cardiac chambers |
| WO1996034567A1 (en) | 1995-05-02 | 1996-11-07 | Heart Rhythm Technologies, Inc. | System for controlling the energy delivered to a patient for ablation |
| WO1996035469A1 (en) | 1995-05-10 | 1996-11-14 | Cardiogenesis Corporation | System for treating or diagnosing heart tissue |
| US5840059A (en) | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
| DE19537084A1 (en) | 1995-10-05 | 1997-04-10 | Sievers Hans Hinrich Prof Dr M | Catheter for transmyocardial revasculation with guidable multi=ID main catheter |
| AU721034B2 (en) | 1996-02-15 | 2000-06-22 | Biosense, Inc. | Catheter based surgery |
| US5769843A (en) | 1996-02-20 | 1998-06-23 | Cormedica | Percutaneous endomyocardial revascularization |
| US5810836A (en) | 1996-03-04 | 1998-09-22 | Myocardial Stents, Inc. | Device and method for trans myocardial revascularization (TMR) |
| IL118352A0 (en) | 1996-05-21 | 1996-09-12 | Sudai Amnon | Apparatus and methods for revascularization |
| DE29609350U1 (en) | 1996-05-24 | 1996-08-29 | P Osypka Mbh Ges Fuer Medizint | Device for perforating the heart wall |
| US5893848A (en) | 1996-10-24 | 1999-04-13 | Plc Medical Systems, Inc. | Gauging system for monitoring channel depth in percutaneous endocardial revascularization |
| EP0984727A4 (en) | 1996-11-08 | 2000-05-24 | Thomas J Fogarty | Transvascular tmr device and method |
| US5944716A (en) | 1996-12-09 | 1999-08-31 | Scimed Life Systems, Inc. | Radio frequency transmyocardial revascularization corer |
| JP4236014B2 (en) | 1997-01-08 | 2009-03-11 | バイオセンス・ウェブスター・インコーポレイテッド | Monitoring myocardial vascular regeneration |
| US5913853A (en) | 1997-01-30 | 1999-06-22 | Cardiodyne, Inc. | Laser energy device and procedure for forming a channel within tissue |
| US5931787A (en) | 1997-02-11 | 1999-08-03 | Tetrad Corporation | Sheath and methods of ultrasonic guidance for biopsy and catheter insertion |
| US5968059A (en) | 1997-03-06 | 1999-10-19 | Scimed Life Systems, Inc. | Transmyocardial revascularization catheter and method |
| US5827203A (en) | 1997-04-21 | 1998-10-27 | Nita; Henry | Ultrasound system and method for myocardial revascularization |
| EP1001708A1 (en) | 1997-08-07 | 2000-05-24 | Cardiogenesis Corporation | System and method of intra-operative myocardial revascularization using pulsed sonic energy |
| US5889915A (en) | 1997-08-07 | 1999-03-30 | Hewton; Alfred F. | Digital storage device for a television |
| US5911729A (en) | 1997-08-13 | 1999-06-15 | United States Surgical Corporation | Electrocautery coring using solid needle |
| US6063082A (en) | 1997-11-04 | 2000-05-16 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization basket delivery system and radiofrequency therapeutic device |
| US6286512B1 (en) | 1997-12-30 | 2001-09-11 | Cardiodyne, Inc. | Electrosurgical device and procedure for forming a channel within tissue |
| ES2293473T3 (en) | 1998-02-05 | 2008-03-16 | Biosense Webster, Inc. | INTRACARDIAC ADMINISTRATION OF FARMACO. |
| US6095981A (en) | 1998-07-01 | 2000-08-01 | The Regents Of The University Of California | Apparatus for attachment of needle or catheter to endoluminal ultrasound probe |
| US6312402B1 (en) | 1998-09-24 | 2001-11-06 | Ekos Corporation | Ultrasound catheter for improving blood flow to the heart |
| US6283935B1 (en) | 1998-09-30 | 2001-09-04 | Hearten Medical | Ultrasonic device for providing reversible tissue damage to heart muscle |
| US6287297B1 (en) | 1999-03-05 | 2001-09-11 | Plc Medical Systems, Inc. | Energy delivery system and method for performing myocardial revascular |
| US6224566B1 (en) * | 1999-05-04 | 2001-05-01 | Cardiodyne, Inc. | Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium |
| CA2312142A1 (en) | 2000-06-22 | 2001-12-22 | An-Go-Gen Inc. | Injection system for gene delivery |
| US6508783B2 (en) * | 2001-03-14 | 2003-01-21 | Scimed Life Systems, Inc. | Ultrasound method for revascularization and drug delivery |
-
2001
- 2001-03-14 US US09/808,624 patent/US6508783B2/en not_active Expired - Fee Related
-
2002
- 2002-02-07 JP JP2002572889A patent/JP4125130B2/en not_active Expired - Fee Related
- 2002-02-07 EP EP02707731A patent/EP1370182A2/en not_active Ceased
- 2002-02-07 CA CA2440122A patent/CA2440122C/en not_active Expired - Fee Related
- 2002-02-07 AU AU2002242120A patent/AU2002242120A1/en not_active Abandoned
- 2002-02-07 WO PCT/US2002/003589 patent/WO2002074175A2/en active Application Filing
-
2003
- 2003-01-15 US US10/346,890 patent/US6702775B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002242120A1 (en) | 2002-10-03 |
| JP2004528884A (en) | 2004-09-24 |
| US6702775B2 (en) | 2004-03-09 |
| WO2002074175A2 (en) | 2002-09-26 |
| EP1370182A2 (en) | 2003-12-17 |
| US6508783B2 (en) | 2003-01-21 |
| JP4125130B2 (en) | 2008-07-30 |
| US20030109821A1 (en) | 2003-06-12 |
| CA2440122A1 (en) | 2002-09-26 |
| US20020133101A1 (en) | 2002-09-19 |
| WO2002074175A3 (en) | 2003-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2440122C (en) | Ultrasound method for revascularization and drug delivery | |
| US7537588B2 (en) | Lateral needle injection apparatus and method | |
| CA2246332C (en) | Catheter based surgery | |
| US6613017B1 (en) | Controlled depth injection device and method | |
| JP4224608B2 (en) | Infusion therapy equipment | |
| US20150265343A1 (en) | Anatomical structure access and penetration | |
| US20020077687A1 (en) | Catheter assembly for treating ischemic tissue | |
| US20010023346A1 (en) | Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium | |
| US20020095124A1 (en) | Lateral needle-less injection apparatus and method | |
| EP1545314B1 (en) | Cardiac ablation using microbubbles | |
| CA2362921A1 (en) | Pmr catheter | |
| CN111202581B (en) | Radio frequency ablation catheter for hypertrophic cardiomyopathy operation | |
| WO2009151478A1 (en) | Needle injection catheter | |
| CA2392559A1 (en) | Needle-less injection apparatus and method | |
| WO2002011625A2 (en) | Percutaneous transluminal myocardial implantation device and method | |
| EP1205156A2 (en) | Injection catheter with needle electrode | |
| US6149649A (en) | Radio frequency transmyocardial revascularization channel formation | |
| US20090118673A1 (en) | Needle injection catheter | |
| US20020121280A1 (en) | Method for myocardial revascularization | |
| WO2002047750A2 (en) | Catheter assembly for treating ischemic tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140207 |